Single Administration of Intracameral Bimatoprost Implant 10 µg in Patients with Open-Angle Glaucoma or Ocular Hypertension
Open Access
- 28 May 2022
- journal article
- research article
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 11 (4) , 1517-1537
Abstract
Introduction This study evaluated the intraocular pressure (IOP)-lowering efficacy and safety of a single intracameral administration of bimatoprost implant 10 µg in adults with open-angle glaucoma or ocular hypertension. Methods Two identically designed, randomized, 20-month, parallel-group, phase 3 clinical trials (one study eye/patient) compared three administrations of 10- or 15-µg bimatoprost implant (day 1, weeks 16 and 32) with twice-daily topical timolol maleate 0.5%. An open-label, 24-month, phase 1/2 clinical trial compared one or two implants administered in the study eye with once-daily topical bimatoprost 0.03% in the fellow eye. Separate analyses of the pooled phase 3 and phase 1/2 study datasets evaluated outcomes in the 10-µg bimatoprost implant and comparator treatment arms after a single implant administration, up to the time of implant re-administration or rescue with IOP-lowering medication. Results In the phase 3 studies, 10-µg bimatoprost implant single administration demonstrated IOP reductions (hour 0) of 4.9–7.0 mmHg through week 15 from a mean (standard deviation, SD) baseline IOP of 24.5 (2.6) mmHg (n = 374); IOP in the topical timolol BID group was reduced by 6.0–6.3 mmHg from a mean (SD) baseline IOP of 24.5 (2.6) mmHg (n = 373). In the phase 1/2 study (n = 21), median time to use of additional IOP-lowering treatment (Kaplan–Meier analysis) was 273 days (approximately 9 months), and 5 of 21 enrolled patients (23.8%) required no additional IOP-lowering treatment up to 24 months after single administration. In each study, after a single implant administration there were no reports of corneal edema, corneal endothelial cell loss, or corneal touch, and no patients had 20% or greater loss in corneal endothelial cell density. Conclusions Bimatoprost implant single administration lowers IOP and has a favorable safety profile. Additional studies are needed to further evaluate the duration of effect and factors predicting long-term IOP lowering after a single implant administration. Trial registration numbers ClinicalTrials.gov NCT02247804, NCT02250651, and NCT01157364.Keywords
Funding Information
- Allergan, an AbbVie company
This publication has 21 references indexed in Scilit:
- The Most Common Barriers to Glaucoma Medication AdherenceOphthalmology, 2015
- Evaluation of eye drop administration technique in patients with glaucoma or ocular hypertensionCurrent Medical Research and Opinion, 2013
- Twenty-Four–Hour Pattern of Intraocular Pressure in Untreated Patients with Ocular HypertensionInvestigative Ophthalmology & Visual Science, 2013
- The Relationship between Glaucoma Medication Adherence, Eye Drop Technique, and Visual Field Defect SeverityOphthalmology, 2011
- Biodegradable Implants for Sustained Drug Release in the EyePharmaceutical Research, 2010
- Do Adherence Rates and Glaucomatous Visual Field Progression Correlate?European Journal of Ophthalmology, 2010
- Comparing Adherence and Persistence Across 6 Chronic Medication ClassesJournal of Managed Care Pharmacy, 2009
- Adherence with Topical Glaucoma Medication Monitored ElectronicallyOphthalmology, 2009
- Review of Corneal Endothelial Specular Microscopy for FDA Clinical Trials of Refractive Procedures, Surgical Devices, and New Intraocular Drugs and SolutionsCornea, 2008
- Noncompliance with Ocular Hypotensive Treatment in Patients with Glaucoma or Ocular HypertensionAn Evidence-Based ReviewOphthalmology, 2005